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Abstract
Polyploidization frequently precedes tumorigenesis but also
occurs during normal development in several tissues. Hepatocyte
ploidy is controlled by the PIDDosome during development and
regeneration. This multi-protein complex is activated by super-
numerary centrosomes to induce p53 and restrict proliferation of
polyploid cells, otherwise prone for chromosomal instability.
PIDDosome deficiency in the liver results in drastically increased
polyploidy. To investigate PIDDosome-induced p53-activation in
the pathogenesis of liver cancer, we chemically induced hepato-
cellular carcinoma (HCC) in mice. Strikingly, PIDDosome defi-
ciency reduced tumor number and burden, despite the inability
to activate p53 in polyploid cells. Liver tumors arise primarily
from cells with low ploidy, indicating an intrinsic pro-tumori-
genic effect of PIDDosome-mediated ploidy restriction. These
data suggest that hyperpolyploidization caused by PIDDosome
deficiency protects from HCC. Moreover, high tumor cell density,
as a surrogate marker of low ploidy, predicts poor survival of
HCC patients receiving liver transplantation. Together, we show
that the PIDDosome is a potential therapeutic target to manipu-
late hepatocyte polyploidization for HCC prevention and that
tumor cell density may serve as a novel prognostic marker for
recurrence-free survival in HCC patients.
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Introduction
Hepatocellular carcinoma (HCC) represents the sixth most common
cancer globally and is ranked as fourth leading cause of cancer-
related mortality, with steadily increasing incidence (Villanueva,
2019). HCC almost exclusively develops on the background of
chronic liver disease such as viral hepatitis or steatohepatitis and
cirrhosis (Villanueva, 2019). Due to common late presentation with
extensive disease, curative therapy is challenging and can only be
provided by liver resection or transplantation (Sapisochin & Bruix,
2017). Thus, a detailed understanding of the molecular mechanisms
underlying hepatocarcinogenesis is essential for disease prevention
as is the identification of new therapeutic targets.
Liver cells are largely polyploid, a feature usually linked to chro-
mosomal instability and subsequent aneuploidy, which is to some
degree seen already in healthy hepatocytes (Knouse et al, 2014;
Sladky et al, 2020). In most other cell types, polyploidy and chromo-
somal instability are considered to put cells at risk for malignant
transformation (Ganem et al, 2007; Lens & Medema, 2019). Of note,
more than one third of all human cancers is predicted to arise from
tetraploid intermediates highlighting the significance of tight ploidy
control (Zack et al, 2013).
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One of the most frequently inactivated genes in HCC is the major
tumor suppressor gene TP53, which is mutated in about 30% of all
patients (Lee, 2015). p53 is activated by various triggers, including
DNA damage, extended mitotic timing or ploidy increases and extra
centrosomes, complex structures that organize the mitotic spindle of
animal cells. Active p53 restricts proliferation, induces cell death,
and orchestrates DNA repair to control genomic integrity and to
prevent cancer (Kastenhuber & Lowe, 2017). Remarkably though,
p53-induced cell death can also promote liver cancer as loss of func-
tional parenchyma fuels compensatory proliferation in the presence
of DNA damage (Qiu et al, 2011). Moreover, p53-associated activa-
tion of p21-induced cell cycle arrest can allow the survival of cells
with altered genomes (Wang et al, 1997; De La Cueva et al, 2006;
Jackson et al, 2012). Thus, p53 activation is not unambiguously
tumor suppressive and its effects on carcinogenesis are clearly
context dependent (Qiu et al, 2011).
Among all the different signals activating p53, it is the presence
of supernumerary centrosomes that indicate a desired but also an
aberrant increase in cellular ploidy (Andreassen et al, 2001;
Godinho & Pellman, 2014). Extra centrosomes can potentially
promote chromosomal instability in subsequent multipolar cell divi-
sions, priming cells for aneuploidy (Bakhoum & Compton, 2009;
Godinho & Pellman, 2014; Levine et al, 2017). Consistently, aber-
rant centrosome numbers are frequently found in human cancer
(Chan, 2011; Godinho & Pellman, 2014). The molecular mechanism
linking extra centrosomes to p53 activation involves the PIDDo-
some, a multi-protein complex which is formed by PIDD1 and
RAIDD to activate caspase-2 (Tinel & Tschopp, 2004; Fava et al,
2017), a protease with documented tumor-suppressive capacity (Ho
et al, 2009; Ribe et al, 2012; Parsons et al, 2013; Puccini et al,
2013a) as well as regulatory roles in liver metabolism (Wilson et al,
2015; Kim et al, 2018).
Caspases are best-known for their roles in inflammation and cell
death (Van Opdenbosch & Lamkanfi, 2019). The PIDDosome and
caspase-2, however, are essential to control cellular ploidy by
surveillance of centrosome numbers (Fava et al, 2017). The pres-
ence of supernumerary centrosomes indicates cell cycle defects lead-
ing to polyploidization, such as aborted mitoses or incomplete
cytokinesis, and is sensed by PIDD1, residing at the mother centriole
(Fava et al, 2017). Formation of the PIDDosome complex leads to
caspase-2 activation, which in turn inactivates the E3-ligase MDM2
that targets p53 for proteasomal degradation. This stabilizes p53
resulting in transcriptional induction of p21 to arrest the cell cycle
(Oliver et al, 2011; Fava et al, 2017). Hence, the PIDDosome
prevents proliferation of cells amplifying centrosomes or following a
tetraploidization step, both events associated with tumor initiation
and progression (Ganem et al, 2007; LoMastro & Holland, 2019;
Lens & Medema, 2019). As such, the PIDDosome should exert
tumor-suppressive functions that may explain observations of
increased rates of tumor formation in mice lacking caspase-2, chal-
lenged by oncogenic drivers such as MYC or ERBB2, or concomitant
ATM loss (Ho et al, 2009; Manzl et al, 2012; Parsons et al, 2013;
Puccini et al, 2013b).
We recently showed that the PIDDosome controls physiological
polyploidization in the liver. Hepatocytes utilize this multi-
protein complex to control the upper limit of liver ploidy during
development and regeneration. In the liver, expression
of the centrosome-sensing component PIDD1 and the executioner
component, caspase-2, is coupled to proliferation, as it is controlled
by antagonizing members of the E2F transcription factor family,
known for their essential role in ploidy control (Conner et al, 2003;
Pandit et al, 2012; Chen et al, 2012). The activating transcription
factor E2F1 induces Pidd1 and Casp2 expression which allows
induction of the PIDDosome-p53-p21 axis to restrict further prolifer-
ation of polyploid hepatocytes. This is counteracted by E2F7 and
E2F8 repressing PIDDosome transcription to allow for proliferation
in a polyploid state in the presence of extra centrosomes (Sladky
et al, 2020). Loss of either PIDDosome component drastically
increases hepatocyte ploidy. While liver function seems unaffected,
the degree of aneuploidy is relatively higher as this is linked to the
basal ploidy state, but not limited by PIDDosome-induced p53
activity itself (Sladky et al, 2020).
Based on the above, we hypothesized that the PIDDosome path-
way is not only upstream of the tumor suppressor p53 but also regu-
lates the degree of hepatocyte polyploidy and aneuploidy in
response to extra centrosomes to prevent carcinogenesis (Serçin
et al, 2016; Levine et al, 2017). Hence, we investigated experimen-
tally whether PIDDosome-mediated p53 activation limits HCC devel-
opment, progression, or tumor karyotype evolution. Unexpectedly,
our results document a tumor-promoting role for p53-dependent
ploidy restriction in liver cancer and that the proliferation of tetra-
ploid cells does not drive aneuploidy in HCC. Furthermore, our find-
ings identify the PIDDosome as a potential drug-target in HCC.
Results
PIDDosome-induced p53 activation facilitates DEN-induced
liver tumorigenesis
The PIDDosome plays a crucial role in restricting liver ploidy during
development and regeneration in hepatocytes acting upstream of
p53 in response to cytokinesis failure-induced centrosome accumu-
lation (Fava et al, 2017; Sladky et al, 2020). Thus, we wanted to test
whether PIDDosome-mediated p53 activation limits tumorigenesis
in the liver. To address this question, we used the DEN-driven
model for chemically induced HCC in wt and mice lacking either
Casp2, Raidd/Cradd, or Pidd1. The livers were isolated and
analyzed 10 months after DEN injection (Fig 1A). Liver tumors, as
hepatocellular adenoma and carcinoma, developed in all genotypes
and in all mice (except for one) and were associated with the pres-
ence of pre-neoplastic lesions in the surrounding non-tumorous
tissue (Fig EV1A–C). Serum levels of key hepatic parameters such
as aminotransferases (ALT, AST), total bilirubin, and urea were
comparable between genotypes while lower cholesterol and
triglyceride levels were found in PIDDosome-deficient animals
(Fig EV1D), a finding in line with a proposed role of caspase-2 in de
novo lipogenesis (Kim et al, 2018). The grade of inflammation and
types of immune infiltrates were similar across genotypes, although
more plasma cells were found in RAIDD-deficient tumors (Fig EV1E
and F).
Despite similar malignancy in terms of infiltrating growth or
tumor necrosis across genotypes, wt livers showed a significantly
higher number of surface tumors per liver when compared to
PIDDosome-deficient mice (Fig 1B and E). Moreover, histopatho-
logical examination of non-tumorous liver tissue revealed that the
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incidence of pre-neoplastic lesions was also higher in wt mice
(Fig EV1C). In line, the total tumor load was clearly higher in wt
animals, reflected here by the cumulative diameter of surface
tumors (Fig 1C). Interestingly, large tumors (> 8 mm) tended to
occur more frequently in PIDDosome-deficient mice (Fig EV1G),
which likely explains the comparable liver to body weight ratios
(Fig 1D).
DEN-induced liver tumors upregulate caspase-2 expression
Adult mouse hepatocytes express neither caspase-2 protein nor
appreciable levels of Pidd1 mRNA (Sladky et al, 2020), raising the
question how the absence of the PIDDosome may affect tumorigene-
sis. Hence, we tested mRNA and protein levels of caspase-2 and
RAIDD as well as Pidd1 transcripts in DEN-induced HCC. Consistent
with our previous results, caspase-2 protein levels were found to be
barely detectable in non-tumorous, presumably healthy and largely
quiescent liver tissue. Interestingly, however, caspase-2 protein was
found readily expressed in all wt tumors tested, as was p53 itself
(Fig 2A). The same trends were observed for transcript levels of
Casp2 and Pidd1 in tumor tissue (Fig EV2A). Due to the lack of suit-
able antibodies, we could not confirm increased PIDD1 protein
expression in tumor tissue. Notably, we found consistent and simi-
lar RAIDD expression in both healthy liver and tumor tissue
(Figs 2A and EV2A).
As the PIDDosome signals upstream of p53 to limit cell cycle
progression in response to extra centrosomes, we next assessed
proliferation rates in liver tumors and non-tumorous liver tissue by
Ki67 staining for flow cytometry and immunohistochemistry. In
hepatic non-tumorous tissue, proliferation rates were low but simi-
lar in all genotypes tested. Despite appreciable differences in tumor
size between wt and PIDDosome-deficient mice, Ki67 staining indi-
cated that tumor-proliferation rates were in a comparable range,
with a weak increase notable by flow cytometry only in the absence
of caspase-2 (Fig 2B). Immunohistochemistry, however, failed to
confirm significant increases in Ki67+ tumor cells in Casp2/ mice
(Fig EV2B). Also, mRNA expression of the cancer stem cell (CSC)
markers CD90 (Thy1) and CD133 (Prom1) (Yamashita & Wang,
2013) was not substantially different between wt and Casp2/ liver
tumors (Fig EV2C). This suggests that the PIDDosome-regulated p53
response facilitates tumor initiation but not tumor progression.
Hence, we closely analyzed PIDDosome-dependent p53 activation at
the time of DEN injection. 15-day-old wt and Pidd1/ mice were
injected with DEN or PBS, as a control (Fig 2C). After 8h, both
genotypes showed highly comparable induction of the DNA-damage
marker phospho-histone cH2AX, as well as of p53 itself. 48h after
injection, the levels of cH2AX and p53 were still comparable
between genotypes suggesting that the DNA-damage response and
p53 activation do not depend on PIDD1 under these conditions
(Fig 2D). Of note, at that time, the degree of polyploidization,
assessed by the percentage of cells showing binucleation, is still low
(Figs 2E and EV2D). Alternatively, DEN-injected mice were weaned
at P19 and analyzed 5 days later. At this time point, the PIDDosome





Figure 1. Loss of PIDDosome function reduces tumor formation in DEN-induced HCC.
A Male wt and PIDDosome-deficient mice were injected with 25 mg/kg DEN at the age of 15 days, and their livers were analyzed 10 months later.
B Numbers of surface tumors per liver were counted.
C The cumulative diameter of all surface tumors per liver per mouse reflects the overall tumor load.
D Weight of the livers including tumor mass relative to the body weight (LW/BW ratio) was recorded.
E Representative pictures of total livers with tumors of the indicated genotypes.
Data information: Open symbols in graphs (B–D) represent the mice shown in (E). wt n = 22, Casp2/ n = 11, Raidd/ n = 14, Pidd1/ n = 15. The line in (B–D)
represents the median value of each group, and statistical significance was determined by one-way ANOVA with multiplicity correction (Sidak–Holm) and defined as
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; scale bar in (E) represents 1 cm.
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during the programmed polyploidization process (Sladky et al,
2020). Consistent with prior results, PIDD1-dependent p53 activa-
tion was seen only at this time point. Despite a clear background
signal for p53 caused by persisting DNA damage, the levels of p53
were now clearly lower in DEN-treated Pidd1/ mice and barely
detectably in PBS controls (Fig 2D). Together, this shows that the
PIDDosome does not contribute to p53 activation after DEN injec-
tion. DNA damage was reported to induce centrosome amplification
in certain conditions (Dodson et al, 2004). To test whether DEN
could induce PIDDosome activation via this route, we assessed
centriole number at the time of injection and 48h later by
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Immunofluorescence of b-catenin was used to discriminate cell
borders. Clearly, centriole number corresponded to the number of
nuclei per cell in both genotypes and did not increase upon DNA
damage (Fig 2F and G). Moreover, differences in the level of the
enzyme Cyp2E1, needed to convert DEN into a DNA-alkylating
intermediate, could also be excluded (Fig EV2E). Thus, we conclude
that the PIDDosome is activated only after weaning to control the
degree of polyploidization, but not upon DEN-induced DNA damage.
Hepatocyte ploidy defines the tumor risk independent of
caspase-2 and the PIDDosome
Based on the above, we reasoned that the unexpected reduction in
liver tumors observed in mice lacking essential PIDDosome compo-
nents might be linked to its function in ploidy restriction. As DEN-
induced DNA damage and compensatory proliferation occur mainly
in diploid cells after DEN injection, tumors may arise from a low
ploidy state and hence the ploidy increase caused by PIDDosome
deficiency at the time of weaning may become protective. To test
this hypothesis, we assessed the ploidy state of murine DEN-
induced tumor tissue (T) and matched non-tumorous liver tissue
(NT). Remarkably, in tumor tissue the numbers of binucleated and
hence clearly polyploid cells per field were significantly reduced and
comparable in all tumors across genotypes. In contrast, PIDDosome-
deficient non-tumorous tissue (NT) tended to harbor more binucle-
ated hepatocytes when compared to wt livers (Fig 3A and B),
consistent with our previous findings (Sladky et al, 2020). More-
over, we measured the ploidy of nuclei isolated from non-tumorous
or tumor tissue which were stained with propidium iodide to assess
DNA content by flow cytometry (Fig EV3A and B). Similar to binu-
cleation, tumor cell nuclear ploidy, here exemplified by the percent-
age of octaploid nuclei, frequently found in healthy tissue (Celton-
Morizur, 2010), was clearly decreased in tumor tissue of Casp2/
and comparable to that found in wt mice. The same trend was
observed for Pidd1/ tumors. Curiously, Raidd/ tumors did not
show this effect (Fig 3C and D). Yet, all tumors in all genotypes
tested showed lower levels of polyploidy, independent of the basal
ploidy state of the surrounding parenchyma (Fig 3A). This supports
the idea that HCC initiates from cells with low ploidy levels which
may have a higher risk of loss of heterozygosity (LOH) of certain
tumor suppressors, and thus, are more likely to transform.
Aneuploidy in HCC is linked to basal tumor cell ploidy but not
limited by caspase-2
In the healthy liver the degree of aneuploidy increases with the poly-
ploidy state of hepatocytes (Sladky et al, 2020). Of note, caspase-2
was reported to eliminate aneuploid cancer cells in vitro and possi-
bly also in patients with colorectal cancer (Dawar et al, 2016;
López-Garcı́a et al, 2017). Therefore, we wanted to determine the
degree of copy number variation (CNV) in wt and Casp2/ liver
tumors to assess the impact of PIDDosome loss on genomic stability
and hence tumor evolution after transformation. To this end, we
subjected diploid and tetraploid nuclei isolated from wt or Casp2/
tumors to whole genome sequencing. Per tumor and ploidy state, 30
cells were pooled and subsequently sequenced to determine CNVs.
Analysis of these mini-bulks allows conclusions on overall aneu-
ploidy but also intra-tumor heterogeneity as reflected by non-integer
copy number states (Fig 4A). In line with previous results in healthy
liver (Sladky et al, 2020), the degree of CNV rises with the basal
ploidy state but this phenomenon was independent of caspase-2
(Fig 4A and B), and hence, presumably, the entire PIDDosome, as
well as PIDDosome-induced p53 activity. Together, this excludes a
direct role for caspase-2 in aneuploidy tolerance, at least in hepato-
cellular carcinoma.
Caspase-2 and PIDD1 are upregulated in human HCC and
correlate with poor prognosis
Since we observed increased levels of caspase-2 in murine tumor
samples, we next tested the levels of each PIDDosome component
in human HCC tumors and matched non-tumorous hepatic tissue.
Similar to the results obtained in mice, we found caspase-2 and
PIDD1 protein to be clearly elevated in human tumor tissue
compared to matched non-tumorous liver. Like in mice, RAIDD
protein levels were comparable between tumor and healthy tissue
(Figs 5A and EV4A). As reported before, cytokinesis failure caused
by inhibition of Aurora B kinase activates the PIDDosome pathway
◀ Figure 2. DEN-induced liver tumors upregulate caspase-2 expression without a direct effect of DEN on PIDDosome activation.A Immunoblots of wt non-tumorous (NT) and tumor (T) tissue lysates were probed for CASP2, RAIDD, and p53. HSP90 and PonceauS protein staining served as loading
controls.
B Proliferation of tumor tissue was determined by the percentage of Ki67-positive nuclei analyzed by flow cytometry. T: wt n = 17, Casp2/ n = 11, Raidd/ n = 10,
Pidd1/ n = 8; NT: wt n = 12, Casp2/ n = 11, Raidd/ n = 7, Pidd1/ n = 5. N-numbers refer to biological replicates.
C Experimental outline: 15-day-old (P15) female and male wt and Pidd1/ mice were injected with DEN (25 mg/kg) or PBS at t(0). The livers were analyzed after t(8 h)
and t(48 h), or the mice were weaned at P19 to induce polyploidization and livers harvested 5 days later t(weaning + 5 d). t(8 h) PBS: wt n = 5, Pidd1/ n = 5; DEN:
wt n = 3, Pidd1/ n = 3. t(48 h) PBS: wt n = 3, Pidd1/ n = 3; DEN: wt n = 5, Pidd1/ n = 3. t(weaning + 5 d) PBS: wt n = 3, Pidd1/ n = 3; DEN: wt n = 3,
Pidd1/ n = 3.
D Immunoblots of the experiment described in (C) at t(8 h), t(48 h), and t(weaning + 5 d) for CASP2, RAIDD, p53, cH2AX, and HSP90 expression as loading control.
E The number of binucleated hepatocytes per field was counted on H&E-stained paraffin sections of PBS treated wt and Pidd1/ mice at t(0 h) and at t(48 h) after
PBS or DEN treatment. N-numbers refer to biological replicates.
F Immunofluorescence of the same livers shown in (E) performed for the distal centriolar protein CP110 to stain centrioles, b-catenin for cell borders, and DAPI to stain
DNA. Representative images of a mononucleated hepatocyte with 2 centrioles and a binucleated hepatocyte with 4 centrioles are shown.
G Centriole number was quantified with respect to the number of nuclei per cell in wt and Pidd1/ livers at the time points described in (E); n = 3 biological replicates.
Data information: Data in (B) are represented as median, (E, G) as mean  SEM, statistical significance was determined by one-way ANOVA with multiplicity correction
(Sidak–Holm); *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. Scale bar size in (F) represents 10 µm.
Source data are available online for this figure.
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in human HCC cell lines (Fig EV4B) (Sladky et al, 2020). Based on
this observation, we wondered if CASP2 or PIDD1 mRNA expression
levels may have prognostic value in HCC. Probing the Provisional
Liver Hepatocellular Carcinoma TCGA data set we found that CASP2
and PIDD1 transcript levels are significantly upregulated in human
HCC across all disease stages. Remarkably, CASP2 mRNA levels
were even higher in patients lacking functional p53. In contrast,
RAIDD expression showed the opposite trend (Fig 5B). In this data
set, high CASP2 expression correlated with reduced disease-free
survival. This correlation, however, was not seen for PIDD1 and
RAIDD expression (Fig 5C).
CASP2 and PIDD1 expression correlates with that of
markers of proliferation
CASP2 and PIDD1 expression is linked to proliferation of primary
hepatocytes as both are transcriptional targets of E2F transcription
factors (Sladky et al, 2020). Thus, we suspected that the observed
effects on expression and survival in HCC patients could be due to
increased proliferation rates in these tumors which may even be
increased further in the absence of p53. Consistently, expression
levels of well-known proliferation markers such as Ki67 also corre-





Figure 3. Nuclear ploidy and binucleation are reduced in HCC tumor tissue.
A, B (A) Binucleation was assessed blinded in H&E-stained sections of murine non-tumor (NT) and tumor tissue (T) also shown in (B). T: wt n = 14, Casp2/ n = 11,
Raidd/ n = 10, Pidd1/ n = 10; NT: wt n = 8, Casp2/ n = 10, Raidd/ n = 8, Pidd1/ n = 9. N-numbers refer to biological replicates.
C, D (C) Representative histograms of nuclei stained for DNA, which were isolated from non-tumor and tumor tissue of wt and Casp2/ mice. These animals are
marked as red “x” in the quantification shown in (D) where the degree of polyploidy is reflected as percentage of octaploid nuclei (T: wt n = 17, Casp2/ n = 11,
Raidd/ n = 10, Pidd1/ n = 8; NT: wt n = 12, Casp2/ n = 11, Raidd/ n = 7, Pidd1/ n = 5). N-numbers refer to biological replicates.
Data information: Data are represented as median, statistical significance was determined by one-way ANOVA with multiplicity correction (Sidak–Holm); *P ≤ 0.05,
**P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001; scale bar represents 100 µm.
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survival noted for patients with high CASP2-expressing HCC
(Figs 5B and C, and EV4C). This effect is strongly affected by the
mutational status of p53, indicating that these tumors are more
aggressive. Of note, the disease-free survival of patients with wt p53
was not affected by the CASP2-expression level (Fig EV4D), suggest-
ing again that higher mRNA levels may be linked solely to higher
tumor-proliferation rates and are not predictive for disease outcome
per se. Hence, we employed bioinformatics analyses of the same
TCGA data set to assess which genes are co-regulated with the
PIDDosome in HCC. Strikingly, the hallmark pathways associated
with genes co-expressed with CASP2 were mostly related to prolifer-
ation, including “G2/M checkpoint”, “E2F targets”, and “mitotic
spindle”. Although to a minor extent, the same pattern of co-expres-
sion was found for PIDD1. In contrast, RAIDD expression was not
linked to proliferation markers but, unexpectedly, was found co-
regulated with genes associated with lipid metabolism (Figs 6A and
EV4E). Notably, the expression of CASP2 and PIDD1 positively
correlates with other E2F target genes (Fig 6B). Moreover, CASP2
and PIDD1 expression showed a strong positive correlation with
Ki67 transcript levels while the correlation for RAIDD mRNA with
this proliferation marker was negative (Fig 6C–E).
Taken together, this suggests that the transcriptional upregula-
tion in HCC tumors observed for CASP2 and PIDD1 is directly linked
to the higher proliferation rates in the tumor while the expression of
RAIDD is uncoupled from the proliferative state. Thus, the impact of
the PIDDosome on DEN-driven tumor formation in mice and the
recurrence-free survival in HCC patients is most likely linked to the
key role of the PIDDosome controlling cellular ploidy (and not to
tumor cell proliferation per se).
Tumor ploidy correlates with recurrence-free survival in HCC
Next, we asked whether the interrelation of polyploidy and
murine HCC is also seen in liver cancer patients. Therefore, we
assessed the cell density of tumor and matched non-tumorous
tissue of 223 patients with histologically confirmed HCC by
morphometric image analysis (Fig EV5B and C), as previously
described (Rohr-Udilova et al, 2018). Cell density, or cells per
field, is an indirect, reciprocal read-out for cell size and thus
ploidy. For better data visualization, we used the reciprocal value
of the cell density to calculate a “ploidy index” (1/cell density)
for HCC tumor and non-tumorous tissue samples of each patient.
Of note, the original cell density data were used to determine
statistical significance and the “ploidy index” is used only for
data representation. As shown before (Toyoda et al, 2005; Gentric
et al, 2015; Bou-Nader et al, 2019), the etiology of the underlying
liver diseases impacts on the degree of polyploidy. Non-tumorous
tissue of patients with NASH or HBV infection was significantly
A B
Figure 4. Caspase-2 has no impact on the degree of aneuploidy in HCC.
Copy number variations were determined using whole genome sequencing of 30 nuclei “mini-bulks” isolated from Casp2/ or wt tumors (n = 11 per genotype). Diploid
and tetraploid pools of tumor cell nuclei were analyzed separately.
A, B (A) Representative dot plots show the degree of aneuploidy and heterogeneity and are quantified in (B, empty symbols). Data are represented as median, statistical
significance was determined by one-way ANOVA with multiplicity correction (Sidak–Holm); *P ≤ 0.05, **P ≤ 0.01. N-numbers refer to biological replicates.
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more polyploid than HCV-infected liver (Fig 7A). Importantly,
similar to our results obtained in mice and in line with previous
studies (Toyoda et al, 2005; Gentric et al, 2015; Bou-Nader et al,
2019), we found that the ploidy in tumor tissue tended to be
lower than in the surrounding liver. This decrease was highly
significant for HCC patients with NASH (Fig 7A). To test whether
the tumor ploidy affects disease outcome across the different
disease etiologies, we pooled all available data on HCC tumor
ploidy and divided the data according to the median HCC tumor
cell density into two groups (Fig 7B). Remarkably, the group with
low HCC tumor ploidy (high cell density) showed a significantly
shorter recurrence-free survival (RFS). Strikingly, multivariate
analysis of age, sex, tumor size, vascular invasion, and tumor cell
density clearly shows that the cell density represents an indepen-
dent prognostic parameter for recurrence-free survival of HCC
patients (Appendix Table S2).
Together, these findings in patients with HCC support the idea
that low-ploid tumors are more proliferative and potentially more
aggressive, increasing the risk of disease recurrence and resulting in
impaired survival also after liver transplantation. As such, tumor
cell density can serve as an independent prognostic marker, while
CASP2 mRNA expression serves as a surrogate of the proliferative





Figure 5. Human HCC frequently upregulate CASP2 and PIDD1 expression.
A Matched patient non-tumor (NT) and tumor tissue (T) samples were analyzed by immunoblotting for CASP2, PIDD1, and RAIDD on membranes a and b. PonceauS
protein staining serves as loading control. The asterisk refers to an unspecific band; “C” and “CC” indicate the functionally active fragments of PIDD1 generated by
autoprocessing, PIDD-C and PIDD-CC. Densitometric quantification of these blots is shown in Fig EV4A.
B mRNA expression analysis of the PIDDosome components in the TCGA Provisional LIHC data set across disease stages. Patients are divided based on the p53
mutation/deletion (mut/del) status. Statistical significance was determined using two-way ANOVA with Tukey’s post hoc analysis. The central band represents the
median, the boxes indicate the 25th and 75th percentile, the whiskers are the 5th and 95th percentiles, and statistical significance was defined as *P ≤ 0.05, **P ≤ 0.01.
C The same data set was analyzed for recurrence-free survival based on high or low expression of CASP2, RAIDD or PIDD1 divided at the median. Statistical significance
was determined using a log-rank test.
Source data are available online for this figure.
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Discussion
We found that loss of PIDDosome-induced p53 function inhibits
hepatocarcinogenesis, pointing toward an oncogenic feature of the
most prominent tumor suppressor in the liver. This notion is
supported by our observation that PIDDosome-deficient animals
develop fewer tumors with an overall reduced tumor burden in
DEN-induced HCC (Fig 1). Notably, DEN treatment induces
compensatory proliferation in response to cell death that is the




Figure 6. Computational analysis of the TCGA Provisional LIHC data set for the expression of PIDDosome components reveals correlation with proliferation
markers.
A Genes co-expressed with the PIDDosome components were examined with respect to the associated hallmark pathways taking positive (pos) and negative (neg)
correlation into account.
B E2F target genes expression was analyzed for correlation with expression of CASP2, RAIDD, and PIDD1 using Spearman’s correlation coefficient. The central band
represents the median, the boxes indicate the 2nd and 3rd quartile, and the whiskers are 1.5 times the interquartile range (n = 200 genes).
C–E Correlation (Pearson) of CASP2, RAIDD, and PIDD1 mRNA with transcript levels of Ki67 in the TCGA data set.
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et al, 2011). Of note, similar findings have been made in a mouse
model of irradiation-driven lymphoma where compensatory prolif-
eration of hematopoietic stem and progenitor cells in response to
radiation-induced apoptosis drives malignancy (Labi et al, 2010;
Michalak et al, 2010). So, next to the induction of cell death, restric-
tion of liver ploidy appears to be another example where p53 can
become involuntarily oncogenic.
We found that CASP2 and PIDD1 expression is increased in
human HCC as well as DEN-induced murine liver cancer (Figs 2, 5
and 6). As both genes are controlled by E2F transcription factors,
their expression is clearly linked to proliferation (Sladky et al,
2020). Hence, the predictive value of CASP2 expression on patient
survival is most likely a secondary effect. As such, data correlating
CASP2 or PIDD1 expression with patient survival need to be inter-
preted with caution as they most likely do not constitute markers of
independent prognostic value.
Our analysis of RAIDD provides several interesting aspects. Aside
from its function within the PIDDosome for liver ploidy control, it is
not co-regulated with CASP2 or PIDD1 and RAIDD-deficient mice
developed the least number of tumors, albeit with the highest ploidy
(Fig 1–5). It remains possible that the differences in phenotype
observed in the absence of RAIDD are driven by a gain of function
of PIDD1, that may then preferentially form alternative signaling
complexes, such as the NEMO-PIDDosome (Sladky et al, 2017), or
the recruitment of caspase-2 into alternative signaling platforms
(Fava et al, 2012). Interestingly, however, RAIDD expression is actu-
ally negatively linked to proliferation but is co-expressed with meta-
bolic enzymes, which points toward a potential role in liver
metabolism. Based on its dual-adaptor domain structure, it seems to
be predestined for functioning within alternative signaling
complexes. Noteworthy here, RAIDD has originally been identified
as a component in the TNF (tumor necrosis factor) receptor signal-
ing complex (Duan & Dixit, 1997), which fuels liver carcinogenesis
(Vucur et al, 2017).
Several recent reports describe the impact of liver cell ploidy on
hepatocarcinogenesis (Zhang et al, 2018a,b; Lin et al, 2020). Our
findings are well in line with this recently emphasized role of high
ploidy as a barrier against HCC, as PIDDosome deficiency signifi-
cantly increases hepatocyte ploidy (Sladky et al, 2020), a phenom-
enon that has been overlooked before in Casp2 mutant mice
(Shalini et al, 2016). Zhang et al (2018a, 2018b) provide solid
evidence that polyploid hepatocytes harboring tumor suppressor
genes in high copy number are protected from LOH and thus, malig-
nant transformation. In accordance, mice harboring a liver-specific
deletion of E2F8 and therefore mostly diploid hepatocytes develop
spontaneous HCC at an early age (Kent et al, 2016). This emerging
hypothesis that challenges the old dogma of polyploidy fostering
aneuploidy and cancer is supported by the fact that both the cellular
and nuclear ploidy levels of murine liver tumor tissue are reduced
when compared to non-tumorous surrounding tissue (Fig 3). Strik-
ingly, the degree of tumor ploidy was similar between wt and the
otherwise highly polyploid Casp2/ and Pidd1/ livers (Fig 3).
Equally noteworthy here, an increased occurrence of CNVs upon
Casp2 deletion or transcriptional repression, as noted in transformed
mouse B cells or human colorectal carcinoma, respectively (Dawar
et al, 2016; López-Garcı́a et al, 2017), was neither found in the
healthy liver (Sladky et al, 2020) nor in chemically induced HCC
(Fig 4). Together, this suggests cell type-specific roles of caspase-2
in the restriction of aneuploidy. Admittedly, our mini-bulk sequenc-
ing approach may be geared to detect preferentially clonal aneuploi-
dies and non-hepatocyte nuclei may skew our results in the 2C
fraction analyzed. Yet, the number of infiltrating inflammatory cells
in tumor tissue is modest and should not substantially alter these
results, as it is also comparable across genotypes (Fig EV1).
In contrast to these previous studies documenting protective
effects of higher hepatocyte ploidy at the time of genotoxic challenge
(Kent et al, 2016; Zhang et al, 2018a,b; Lin et al, 2020), deficiency
in caspase-2, PIDD1 or RAIDD leads to ploidy increases long after
DNA damage has occurred and the DNA-damage response already
ceases (Fig 2). At the time point of DEN injection (P15), most hepa-
tocytes are still diploid (Fig 2), regardless of the genotype (Zhang
et al, 2018b; Sladky et al, 2020). This suggests that polyploidy is not
only protective at the time of mutagenesis, but can delay malignant
transformation also if it occurs at a later stage, as shown in our
study. This observation clearly challenges current thinking about
the tumor-promoting role of polyploidization in cancer. A possible
explanation may be that, for example, a tetraploid cell that had
A
B
Figure 7. The degree of polyploidy differs between etiologies, and low
tumor ploidy correlates with reduced disease-free survival.
A The ploidy index is inferred as 1/cell density of tumorous (T) and non-
tumorous (NT) tissue of HCC patients with different liver diseases. ALD—
alcoholic liver disease (n = 65); HBV—hepatitis B virus infection (n = 24);
HCV—hepatitis C virus infection (n = 85); NASH—non-alcoholic
steatohepatitis (n = 33). Statistical significance was determined by one-way
ANOVA with multiplicity correction (Sidak–Holm); *P ≤ 0.05, **P ≤ 0.01,
***P ≤ 0.001. n-numbers refer to the number of patient samples analyzed.
B All patients were grouped according to HCC tumor cell density as surrogate
for tumor ploidy. Data were divided at the median, and exact patient
numbers are shown in the graphs. Median recurrence-free survival (RFS) for
a period of 10 years for patients with low tumor ploidy was 4.8 years. For
patients with high tumor ploidy, the median RFS could not be defined as
more than 50% of the patients survived without relapse. Patient
characteristics are shown in Appendix Table S1. A log-rank test was used to
determine statistical significance.
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duplicated a driver mutation at the time of weaning, now also
harbors four copies of each tumor suppressor gene. As such, this
gene duplication event shifts the balance in favor of the rheostat of
tumor suppressors even at times long after the initial driver muta-
tion has occurred. This may explain why tumors arise from hepato-
cytes of low ploidy, independent of the overall liver ploidy. As this
low-ploid fraction of hepatocytes is substantially reduced in the
absence of the PIDDosome, the population at risk for transformation
is simply smaller.
Of note, most studies on the interrelation of ploidy and HCC were
performed in mouse models where hepatocyte ploidy was modified
by genetic manipulation of key cell cycle or cytokinesis regulators
(Kent et al, 2016; Zhang et al, 2018a,b; Lin et al, 2020). However,
enhanced polyploidy due to deregulated cell cycle proteins is not
necessarily protective as mice overexpressing CCNE1 show strong
hyperpolyploidization but develop spontaneous liver cancer (Aziz
et al, 2019). This finding challenges former results in support of the
“ploidy-barrier” hypothesis. Yet, as PIDDosome deficiency increases
hepatocyte ploidy without the need for direct manipulation of the
cytokinesis or cell cycle machineries, our study suggests that the
ploidy-barrier can prevent disease, until additional pro-proliferative
signals force polyploid cells to repeatedly re-enter the cell cycle,
e.g., upon inflammation.
Based on the above, it would be interesting to see whether the
degree of ploidy in the human liver inversely correlates with HCC
frequency. However, as HCC in humans is usually associated with
an underlying inflammatory disorder that often changes hepatocyte
ploidy, such a relationship will not easily be established (Toyoda
et al, 2005; Gentric et al, 2015; Bou-Nader et al, 2019). Yet, we
found a clear correlation between HCC tumor cell density and recur-
rence-free survival in our patient cohort (Fig 7). Automated
morphometric cell density analysis as surrogate for the degree of
polyploidy clearly showed that low HCC tumor ploidy is associated
with reduced survival and could serve as independent prognostic
parameter. However, experimental validation of the robustness of
tumor cell density as a measure of cellular ploidy in matched patient
samples subjected to morphometric as well as flow cytometric anal-
ysis is still pending and will be subject of future investigations.
A recent study suggested mononuclear polyploidy as marker for
HCC aggressiveness, as in this cohort patients with highly poly-
ploid, and often p53-mutated tumors, have an increased risk for
recurrence (Bou-Nader et al, 2019). Of note, the patient cohort
investigated by Bou-Nader et al comprised substantially fewer
patients (75 vs. 223) and also the types of underlying diseases differ
between our studies. Together, these differences might explain why
our results, at first sight, appear to contrast the findings by
Bou-Nader and colleagues. Clearly, p53 loss increases polyploidy
tolerance but most certainly increases tumor aggressiveness and
recurrence rates also by other means. Unfortunately, we do not have
the corresponding information regarding p53 status for our patient
cohort to test whether those carrying mutations would show
reduced RFS within the high ploidy group. Further studies will have
to assess whether healthy liver ploidy can indeed serve as an inde-
pendent prognostic marker for the individual risk of HCC develop-
ment. Morphometric analysis of routinely generated H&E-stained
liver tissue biopsies, for example, from healthy donor livers used in
transplant settings, could readily be used to collect data on hepato-
cyte ploidy in the healthy liver for prospective studies.
Taken together, we conclude that the PIDDosome indirectly
impacts on chemically induced hepatocarcinogenesis by limiting
hepatocyte polyploidization during postnatal liver development.
Multiple lines of evidence suggest that caspase-2 is a promising ther-
apeutic target (Sladky & Villunger, 2020). Here, we clearly demon-
strate that caspase-2-mediated ploidy control impacts on HCC
initiation. In addition, caspase-2 has been reported to accelerate
NAFLD and NASH by induction of de novo lipogenesis, which can
culminate in HCC (Machado et al, 2015; Kim et al, 2018; Anstee
et al, 2019). Therefore, inhibition of caspase-2 for treatment of liver
disease could prevent tumorigenesis both by elevated polyploidiza-
tion and preventing the progression of hepatic steatosis.
Materials and Methods
DEN-induced HCC
All animal experiments were approved by the Austrian Bundesminis-
terium für Bildung, Wissenschaft und Forschung (Tierversuchsge-
setz 2012; https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_
2012_I_114/BGBLA_2012_I_114.pdfsig, BGBl I Nr. 114/2012, project
number 66.011/0108/-WF/V/3b/2015). Generation and genotyping
of Casp2/, Raidd/, and Pidd1/ mice were previously described
(O’Reilly et al, 2002; Berube et al, 2005; Manzl et al, 2009). All mice
used were maintained on a C57BL/6N background under standard
housing and enrichment conditions with a 12-h/12-h light/dark cycle.
15-day-old male C57BL/6N wild-type (n = 22), Casp2/ (n = 11),
Raidd/ (n = 14), and Pidd1/ (n = 15) mice were intraperi-
toneally injected during daytime with 25 mg/kg body mass DEN (di-
ethylnitrosamine; Sigma-Aldrich, St. Louis, MO, Cat# N0258, CAS#
55-18-5) diluted in PBS and sacrificed for organ harvesting 10 months
later. The health status of the mice was monitored visually and by
monthly weight measurement. Tumor load was assessed by counting
the number of tumor nodules on the liver surface, by measuring the
size of surfaces tumors using a caliper, and by weighting the livers
including tumors. Tissue samples of liver tumors and non-tumorous
liver tissue were collected and either fixed in 4% paraformaldehyde
or snap-frozen in liquid nitrogen. Blood was collected at the time of
harvest. Serum levels of aspartate aminotransferase (AST), alanine
aminotransferase (ALT), total bilirubin, urea, cholesterol, and triglyc-
erides in the murine HCC models were measured enzymatically
(Cobas analyzer, Roche Diagnostics, Mannheim, Germany) as by
manufacturer’s instruction. For short-term analyses, 15-day-old wt
and Pidd1/ mice were injected with PBS or DEN, as above. Mice
were sacrificed after 8 h or 48 h, or were weaned at the age of
19 days and sacrificed 5 days later (experiment outline Fig 2C).
Livers were flushed with PBS to remove blood and non-liver cells.
Tissue was snap-frozen, fixed in 4% paraformaldehyde, or embedded
and frozen in O.C.T. compound (Sakura Europe, Staufen, Germany,
Cat# SA62550-01).
Isolation of human HCC samples and non-tumorous liver tissue
Tumors and surrounding non-tumorous tissue samples of patients
with histologically confirmed HCC undergoing orthotopic liver
transplantation were collected at the Vienna General Hospital,
Austria. The use of these biopsies for scientific research was
approved by the ethics committee at the Medical University of
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Vienna (#2033/2017), and patients gave informed consent. For the
morphometric analyses, HCC tumor tissue and corresponding adja-
cent non-tumorous liver tissue from 223 patients were evaluated.
Clinical data of the patients are summarized in Appendix Table S1.
Clinical data analysis was performed in accordance with the guideli-
nes of the local Ethics Committee at the Medical University of
Vienna, and all patients gave written informed consent.
Cell line experiments
SNU182 cells were obtained from the lab of Michael Trauner, Medi-
cal University of Vienna, Austria. Cells were cultured 37°C with 5%
CO2 in RPMI 1640 (Sigma-Aldrich, St. Louis, MO, Cat# FG1385)
supplemented with 10% FBS (Cat# A15-151) and Penicillin/Strepto-
mycin (Cat# P11-010, both PAA Laboratories, Pasching, Austria)
and cultures regularly tested for mycoplasma contamination. Treat-
ment with 1 or 2 µM ZM447439 (Selleck Chemicals, Houston, TX,
Cat# S1103) for 48h was started 24h after seeding. Cells were
harvested by trypsinization.
Histopathological examination and immunohistochemistry
Histopathological analysis of H&E-stained 4-µm sections of paraf-
fin-embedded liver was performed by board-certified veterinary
pathologists, Laura Bongiovanni and Alain de Bruin, Dutch Molec-
ular Pathology Centre, Utrecht University, NL. Number and
approximate size of nodules, tumor malignancy, inflammatory
infiltration, tumor necrosis, and binucleation were determined.
Following deparaffinization and rehydration in xylol and ethanol,
the tissue sections of non-tumorous liver and tumor tissue were
treated 10 mM citrate buffer (pH 6.0) for antigen retrieval. Block-
ing was performed in peroxidase solution (1% H2O2/TBS), and
sections were stained consecutively with primary (Rabbit mono-
clonal anti Ki67 (D3B5), Cell Signaling Technology, Danvers, MA,
Cat# CS12202) and secondary (Biotin-SP-goat anti-rabbit Affini-
Pure, Jackson ImmunoResearch Laboratories, West Grove, PA,
Cat# 111-065-144) antibody diluted in 5% goat serum/TBS.
VECTASTAIN ABC Kit (Vector Laboratories, Burlingame, CA, Cat#
PK-6100) and ImmPACT DAB (Vector Laboratories, Burlingame,
CA, Cat# SK-4105) were used for amplification and development.
The immune-stained sections were counterstained with hema-
toxylin, dehydrated, and mounted. Images were acquired on an
Olympus BX45 microscope using cell^B software (version 2.7,
Olympus soft imaging solutions, Shinjuku, Japan). Analysis of
slides and images was performed blinded.
Mini-bulk whole genome sequencing and data analysis
Isolation and sequencing of tumor and liver tissue nuclei was
performed as described before (van den Bos et al, 2019). In brief,
snap-frozen tissues were cut into small pieces and incubated in
nuclei isolation buffer (10 mM Tris–HCl pH 8.0, 320 mM Sucrose,
5 mM CaCl2, 3 mM Mg(Ac)2, 0.1 mM EDTA, 1 mM DTT, 0.1%
Triton X-100). Subsequently, nuclei were isolated from the tissue
homogenate by gently passage through a 70-µm filter using a
syringe plunger and pelleted by centrifugation. The nuclei pellet
was resuspended in PBS containing 2% bovine serum albumin and
10 µg/ml Hoechst 33358 (Thermo Fisher Scientific, Waltham, MA,
Cat# H3569) and 10 µg/ml propidium iodide (Thermo Fisher Scien-
tific, Waltham, MA, Cat# P1304MP). 30 nuclei per tumor were
sorted into a single well for library preparation as described previ-
ously (van den Bos et al, 2019). Sequencing was performed using
a NextSeq 500 (Illumina, San Diego, CA). The resulting sequencing
data were aligned to the murine reference genome (GRCm38) using
Bowtie2 (v2.2.4) (Langmead & Salzberg, 2012). To analyze copy
number variation, the R package AneuFinder (v1.10.1) was used
(Bakker et al, 2016). Following GC-correction, blacklisting of arti-
fact-prone regions (extreme low or high coverage in control
samples), and mappability checks, libraries were analyzed using
the edivisive copy number calling algorithm using 1 Mb bin size,
and modal copy number state according to the expected ploidy
state and the breakpoint detection parameter was set to 0.9. The
aneuploidy score of each library was calculated as average of the
absolute deviation from the expected euploid copy number per
bin.
Isolation of nuclei from snap-frozen tissue
The procedure was adapted for liver and tumor tissue from Berg-
mann & Jovinge, 2012. Snap-frozen tissue was minced with a
scalpel and transferred into tissue lysis buffer (0.32 M sucrose,
10 mM Tris–HCl pH 8, 5 mM CaCl2, 5 mM MgAc, 2 mM EDTA,
0.5 mM EGTA, 1 mM DTT) and homogenized using an Ultra-
Turrax probe homogenizer (IKA, Staufen, Germany) at 20,000 rpm
for 12 s. To extract nuclei from intact cells, the homogenate was
passed three times through a 20 g needle and remaining tissue
pieces were removed by passages through 100- and 70-µm cell
strainers. Nuclei were sedimented by centrifugation at 700 g for
10 min at 4°C and resuspended in 25 ml sucrose buffer (2.1 M
sucrose, 10 mM Tris–HCl pH 8, 5 mM MgAc, 1 mM DTT). For
high-density centrifugation in order to remove cell debris and
enrich for nuclei, BSA-coated ultracentrifugation tubes prefilled
with 10 ml sucrose buffer cushion were carefully overlaid with the
dissolved nuclei pellet and centrifuged for 60 min at 13,000 g
(Beckman, Brea, CA, Avanti S-25, JA25.50 rotor). The supernatant
was discarded, and the isolated nuclei were dissolved in 1 ml
nuclei buffer (0.44 M sucrose, 10 mM Tris–HCl pH 7.4, 70 mM
KCl, 10 mM MgCl2).
Flow cytometry
3 × 106 nuclei in nuclei isolation buffer were centrifuged at 700 g
for 10 min fixed by adding 100 µl BD Cytofix/Cytoperm solution
(BD Biosciences, Franklin Lakes, NJ, Cat# 554714) while vortexing
and incubated for 15 min on ice. After a washing step with 2% BSA
in PBS, nuclei were resuspended in 100 µl Perm/Wash buffer (BD
Biosciences, Franklin Lakes, NJ, Cat# 554714, prediluted 1:10 in
A.D.) and incubated for 10 min at room temperature. Following a
washing step with Perm/Wash, the nuclei were incubated with
A488-conjugated antibody recognizing Ki67 (Alexa Fluor 488 anti-
mouse Ki67 Antibody (16A8), BioLegend, San Diego, CA, Cat#
652417) diluted 1:50 in Perm/Wash for 30 min at room tempera-
ture. Nuclei were washed with 2% BSA in PBS and resuspended
with 1 µg/ml propidium iodide in PBS to stain DNA. The stained
nuclei were directly analyzed by flow cytometry on a LSR Fortessa
(BD).
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Immunofluorescence
O.C.T.-embedded liver cryo-sections of n = 3 wt or Pidd1/ mice per
time point and treatment were fixed in 100%methanol and stained for
CP110 (rabbit polyclonal anti-CP110, Proteintech, Rosemont, IL,
Cat#1278-1-AP) and ß-catenin (mouse monoclonal anti-b-catenin (14),
BD Bioscience, Franklin Lakes, NJ, Cat# 610154). The secondary anti-
bodies used were Alexa 488 goat anti-rabbit (A11031) and Alexa 546
goat anti-mouse (A11030) from Thermo Fisher Scientific, Waltham,
MA. The nuclei were stained with Hoechst 33342 (Sigma-Aldrich, St.
Louis, MO, CAS# 23491-52-3), and the sections were mounted in
Mowiol. Images were acquired (2,048 × 2,048 pixels, bit depth: 16 bit)
on a Zeiss Axiovert 200M microscope with an oil immersion objective
(Ph3 Plan-Neofluar 100×/1.3 oil, 440481, Zeiss, Oberkochen, Germany)
using the acquisition software VisiView 4.1.0.3 (Visitron Systems,
Puchheim, Germany). ImageJ was used to adjust contrast and bright-
ness of the images. Per mouse, 50 cells were analyzed. The number of
nuclei and centrioles was counted manually in a blinded fashion.
Protein isolation and immunoblotting
Snap-frozen tissue of mouse or human origin and cell line pellets
were lysed in Ripa buffer (150 mM NaCl, 50 mM Tris, 1% NP-40,
0.5% sodium deoxycholate 1% SDS, 1 tablet EDTA-free protease
inhibitors). The protein content was determined using Bradford’s
reagent (Bio-Rad, Hercules, CA, 500-0006), and 40–80 µg protein
was used for Western blotting (AmershamTM HybondTM—ECL
nitrocellulose membranes, GE Healthcare, Chicago, IL) with a wet-
transfer system (Bio-Rad, Hercules, CA). Proteins of interest were
detected using antibodies recognizing caspase-2 (rat monoclonal
anti-Casp2 (11B4), Enzo Life Sciences, Farmingdale, NY, Cat# ALX-
804-356; 1:1,000), RAIDD (rabbit polyclonal anti-RAIDD, Protein-
tech, Rosemont, IL, Cat# 10401-1-AP, 1:1,000), PIDD1 (mouse
monoclonal anti-PIDD1 (Anto-1), Enzo Life Science, Cat# ALX-804-
837, 1:500), p53 (Mouse monoclonal anti-p53 (1C12), Cell Signaling
Technology, Danvers, MA, Cat# CS2524), Phospho-Histone H2A.X
(Ser139, Cell Signaling Technology, Danvers, MA, Cat# CS2577),
MDM2 (mouse monoclonal anti-MDM2 (IF2), Thermo Fisher Scien-
tific, Waltham, MA, Cat# MA1113), and HSP90 (mouse monoclonal
anti-Hsp90, Santa Cruz, Dallas, TX, Cat# sc-13119, 1:10,000). HRP-
conjugated secondary antibodies used for detection were diluted
1:5,000 (HRP-mouse anti-rat, Cell Signaling Technology, Danvers,
MA, Cat# CS7077S; HRP-mouse anti-mouse, Dako, Agilent, Santa
Clara, CA, Cat# P0616; HRP-mouse anti-rabbit, Dako, Cat# P0448).
All antibodies used were verified with appropriate controls in the
present and in previous publications (Fava et al, 2017; Sladky et al,
2020). Densitometric quantification was performed using ImageJ.
RNA isolation and quantitative real-time PCR
Snap-frozen tissue was grinded in liquid nitrogen and dissolved in
500 µl TRIzol. RNA was isolated by adding chloroform to 1/5 v/v.
Samples were mixed and incubated at room temperature. After
centrifugation at 12,000 g for 15 min at 4°C, the aqueous phase was
transferred into fresh tubes and the equivalent volume of isopro-
panol was added, mixed, and incubated for 10 min at room temper-
ature. Purified RNA was sedimented by centrifugation and washed
with 75% ethanol. The dried pellets were resuspended in DEPC-
treated A.D., and DNA was digested using RQ1 RNase-Free DNase
kit according to manufacturer’s instructions (Promega, Madison,
WI, Cat#: M6101). Finally, RNA was precipitated again with Glyco-
BlueTM Coprecipitant (Thermo Fisher Scientific, Waltham, MA,
Cat#: AM9515). The RNA content was quantified with a NanoDrop
1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA)
and reverse transcribed into cDNA with iScriptTM cDNA Synthesis
Kit (Bio-Rad, Hercules, CA, Cat#: 1708891) as stated in the manufac-
turer’s instructions. Quantitative real-time PCR was performed on a
StepOnePlus System (Thermo Fisher Scientific, Waltham, MA). The
fluorescence dye-based qRT–PCR using AceQ qPCR SYBR Green
Master Mix (Vazyme, Nanjing, China, Cat#: P410) was performed
according to the manufacturer’s protocol (10 µl 2 × AceQ qPCR
SYBR Green Master Mix, 0.4 µl Rox 1, 0.2 µl Primer Mix, 2 µl
cDNA filled up with A.D. to 20 µl). The following primers were used
at a final concentration of 100 nM for detection of Casp2, Pidd1,
Raidd and Hprt expression: mCasp2 fw: TCTCACATGGTGTGGAA
GGT, mCasp2 rev: AGGGGATTGTGTGTGGTTCT, mPidd1 fw: TGTT
CTGCACAGCAACCTCC, mPidd1 rev: TGGGATATGTCTGGGGGA
CT, mRaidd fw: GCTTATCGGAAGAAATGGAAGCC, mRaidd rev:
GGCCTGTGGTTTGAGCTTTG (Sladky et al, 2020), mHprt fw:
GTCATGCCGACCCGCAGTC, and mHprt rev: GTCCTTCCATAATA
GTCCATGAGGAATAAAC (Schoeler et al, 2019). mRNA expression
of Cyp2E1, Prom1, and Thy1 was assessed using predesigned primer
assays (Integrated DNA Technologies, Inc, Coralville, IA, USA.
Cyp2E1: Mm.PT.58.9617541; Prom1: Mm.PT.58.8851198; Thy1:
Mm.PT.58.14029994). All qPCRs were performed in duplicates. PCR
conditions were as follows: 95°C for 10 min, 40 cycles of (95°C for
15 s and 60°C for 60 s) and a melting curve with 0.3°C increment
steps up to 95°C for 15 s. Results for the gene of interest were
normalized to expression of housekeeping gene Hprt, and relative
expression was calculated using the DDCt method.
Data analysis
Statistical analyses were performed by Prism 7.0.0 (GraphPad Soft-
ware, San Diego, CA). Unpaired Student’s t-test was used for
comparison of two groups, and one-way ANOVA with multiple
comparison correction (Sidak–Holm) was employed if more than
two groups were compared. All relevant comparisons were made,
and non-significant results were not indicated in the figures. Signifi-
cance levels are stated in the respective figure legends.
Gene expression data of hepatocellular carcinoma samples
collected for The Cancer Genome Atlas (TCGA) project (https://
www.cancer.gov/tcga) were downloaded from the GDAC Firehose
website (http://firebrowse.org; 28/01/2018 release) as upper quar-
tile normalized RPKM (UQRPKM) values provided by RSEM. Clini-
cal information on patients, including disease-free survival, was
learned from the revised data set of Liu et al (2018) extracted
recently from the TCGA database. For each patient, the first primary
solid tumor tissue sample in alphabetical order of sample barcodes
was taken into account. Kaplan–Meier curves and log-rank statistics
to compare prognosis in groups were analyzed using the survminer
R package (https://CRAN.R-project.org/package=survminer).
Information on the p53 mutation status was downloaded from
cBioPortal (cbioportal.org).
Pairwise Pearson’s correlation coefficients of gene expression in
hepatocellular carcinoma samples were downloaded from the
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cBioPortal for Ki67, E2F1, CCNA2, PIDD1, RAIDD (CRADD), and
CASP2 (cbioportal.org) (Gao et al, 2013). Genes with a Pearson’s r
value greater than 0.5 or smaller than 0.5 were considered as
co-regulated with the target genes. The resulting gene lists were
subjected to enrichment analysis with the enricher function of
clusterProfiler in R (Yu et al, 2012). As an alternative approach,
Gene Set Enrichment Analysis with all genes ranked by the r value
was also carried out using clusterProfiler. Signature gene sets
including transcription factor targets and GO terms were down-
loaded from the MSigDB database (http://software.broadinstitute.
org/gsea/msigdb) using the msigdbr package (Subramanian et al,
2005).
Cell density measurement
To assess cell density tissue arrays as shown in Rohr-Udilova et al
(2018) were used. Nuclear staining was performed by hematoxylin.
Slide images were digitized using a Pannoramic Midi Slide Scanner
(3Dhistech, Budapest, Hungary). Morphometric characteristics of
single nuclei were evaluated by tissue morphometric analysis of
the digitized slide images using the Tissue Studio software (Defi-
niens, Munich, Germany). On average, 8,710  3,425 cells in
tumor and matched non-tumorous tissue sections were analyzed
per patient. The tissue sections were previously stained for tryptase
to detect mast cells (Rohr-Udilova et al, 2018). Negatively stained
cells were considered for further morphometric analysis. As shown
in Fig EV5B and C, the software allows the detection of nuclei and
cell borders to measure the cell area. To test the impact of nuclear
circularity images of 39 HCC patients were reanalyzed considering
only nuclei with a circularity-index greater than 7 out of 10 for
survival analysis (Fig EV5A). As no difference was seen, all nuclei
stained negatively for tryptase were used for further analysis to
assess cell density (Fig EV5B and C). Recurrence-free survival was
depicted by Kaplan–Meier curves and compared between patient
groups by log-rank Mantel–Cox test using Prism 7.0.0, GraphPad
Software.
Multivariate analysis
The contribution of cell density on the recurrence-free survival of
patients undergoing transplantation for HCC was evaluated. Recur-
rence and/or death were considered as event while patients were
censored at last clinical contact. Parameters associated with recur-
rence-free survival on univariate analysis were tested for their inde-
pendent prognostic impact by Cox regression and stepwise
backward elimination. In total, the analysis included n = 172
patients, as not all data were available for the 223 patients included
in the cell density analysis. Calculations were performed using IBM
SPSS Statistics 25 Software.
Data availability
The single-cell sequencing data set generated in this study is avail-
able on the European Nucleotide Archive (https://www.ebi.ac.uk/
ena/browser/home); Accession number: PRJEB3593.
Expanded View for this article is available online.
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